SUBSCRIBE
SUBSCRIBE

Postmarket research

Drug Development
Nicotine Patch Plus Lozenge Best for Quitting Smoking, National Institutes of Health (NIH) Funded Study
November 3, 2009
 · 
1 min read
Drug Development
Certain Antibiotics May Up Birth Defect Risk, Centers for Disease Control and Prevention (CDC) Study
November 3, 2009
 · 
1 min read
Drug Development
Extending Treatment After Liver Transplant May Benefit Patients With Hepatitis C Recurrence, Henry Ford Hospital Study
November 2, 2009
 · 
1 min read
Drug Development
Switching Immunosuppressants Reduces Cancer Risk In Kidney, Queen Elizabeth Hospital Study
November 2, 2009
 · 
1 min read
Bookmark and Share
Drug Development
Triple-combo Drug Shows Promise Against Antiviral-resistant H1N1, University of Alabama at Birmingham Study
October 30, 2009
 · 
1 min read
Drug Development
Teriparatide Outperforms Alendronate In Treating Steroid-Induced Osteoporosis, University of Alabama at Birmingham Study
October 29, 2009
 · 
1 min read
Bookmark and Share
Drug Development
Antipsychotics Cause Rapid Weight Gain in Youth, Zucker Hillside Hospital and Feinstein Institute for Medical Research Study
October 28, 2009
 · 
1 min read
Bookmark and Share
Drug Development
Anti-Epilepsy Drugs Could Treat Alzheimer’s And Parkinson’s Diseases, Washington University in St. Louis Study
October 28, 2009
 · 
1 min read
Bookmark and Share
Drug Development
Combination Antiretroviral Therapy Effective At Reducing HIV Resistance In Mothers And Babies Following Mother-to-child Transmission, Study Funded by Boehringer Ingelheim Corporation
October 28, 2009
 · 
1 min read
Drug Development
Drug Used For Neuropathic Pain Relieves Discomfort From Abdominal Adhesions, Henry Ford Hospital Study
October 27, 2009
 · 
1 min read
Load More
PRESS RELEASES
News
Tenon(R) Medical Announces First Peer Reviewed Publication of the MAINSAIL(TM) Study Analyzing the First 33 Consecutive Patients from an IRB Approved, Prospective, Multi-Centered, Post-Market Clinical Investigation Utilizing the Catamaran(R) SI Joint Fusion System
September 6, 2024
 · 
8 min read
Drug Development
Corcept Completes Enrollment in Phase 4 CATALYST Trial
April 29, 2024
 · 
3 min read
Business
Parexel and Palantir Expand Collaboration to Accelerate Clinical Data Delivery and Power Clinical Outcomes for Patients
April 25, 2024
 · 
6 min read
Drug Development
Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets
April 16, 2024
 · 
11 min read
Drug Development
Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
January 5, 2024
 · 
10 min read
Drug Development
Dermavant Announces Positive Results from Phase 4 Open-Label Trial of VTAMA® (tapinarof) Cream, 1% for the Treatment of Plaque Psoriasis in the Head and Neck Region in Adults
December 6, 2023
 · 
10 min read
Drug Development
AMGEN PRESENTS NEW RESEARCH IN EARLY PSORIATIC ARTHRITIS AT ACR 2023
November 7, 2023
 · 
17 min read
Drug Development
MannKind Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living With Type 1 Diabetes
November 6, 2023
 · 
3 min read
Drug Development
Dermavant Presents Positive Results from Phase 4 Open-Label Trial of VTAMA® (tapinarof) Cream, 1% for the Treatment of Intertriginous Plaque Psoriasis in Adults at 43rd Annual Fall Clinical Dermatology Conference
October 20, 2023
 · 
10 min read
Drug Development
Teva Phase IV UNITE Study Shows AJOVY® (fremanezumab) Reduced Migraine Attacks and Depression Symptoms in Migraine Sufferers with Major Depressive Disorder
October 17, 2023
 · 
8 min read
Drug Development
CEQUA® (cyclosporine ophthalmic solution) 0.09% Phase 4 Data Showed Sustained Improvement in Dry Eye Disease Signs and Symptoms in Patients Switched From Restasis® (cyclosporine ophthalmic emulsion) 0.05%
October 12, 2023
 · 
10 min read
Drug Development
First-Ever Clinical Trial Exclusively in Black and Hispanic / Latinx People Living With Multiple Sclerosis Shows Genentech’s Ocrevus Effectively Manages Disease Activity
October 11, 2023
 · 
15 min read
Drug Development
CymaBay Initiates AFFIRM, a Phase 3b/4 Study Evaluating the Effect of Seladelpar on Clinical Outcomes in Patients with Cirrhosis due to Primary Biliary Cholangitis
September 21, 2023
 · 
5 min read
Business
Samsung Bioepis & Organon Announce Topline Results from Interchangeability Study of SB5 Humira Biosimilar
August 1, 2023
 · 
15 min read
Drug Development
SKYRIZI® (risankizumab) Achieved Superiority Versus Apremilast for Co-Primary Endpoints Among Adult Patients with Moderate Plaque Psoriasis in Phase 4 Head-to-Head Study
July 26, 2023
 · 
12 min read
Drug Development
Grifols Achieves Positive Topline Results From Phase 4 Study of XEMBIFY® (immune globulin subcutaneous human-klhw) Evaluating Biweekly Dosing Option for Patients
July 20, 2023
 · 
10 min read
Drug Development
Akebia Therapeutics Announces Positive Top-Line Results of Phase 4 IMPACT Study of Auryxia® (ferric citrate) for In-Center and Home Dialysis Patients
June 29, 2023
 · 
7 min read
Drug Development
Additional Data from Phase 4 TEPEZZA® (teprotumumab-trbw) Clinical Trial Presented at the Endocrine Society Annual Meeting Reinforces Efficacy in People with Thyroid Eye Disease (TED) Regardless of Disease Activity or Duration
June 17, 2023
 · 
9 min read
Drug Development
ANDEXXA Phase IV Trial Stopped Early After Achieving Pre-specified Criteria on Hemostatic Efficacy Versus Usual Care
June 5, 2023
 · 
13 min read
Drug Development
Horizon Therapeutics plc Announces Positive Topline Data from TEPEZZA® (teprotumumab-trbw) Phase 4 Clinical Trial in Patients with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)
April 10, 2023
 · 
9 min read
Load More